Stockscreener 앱 받기
11.73
8.41%
0.91
시장 영업 전:
11.87
0.14
+1.19%
전일 마감가:
$10.82
열려 있는:
$10.94
하루 거래량:
1.72M
Relative Volume:
2.69
시가총액:
$923.97M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+18.72%
1개월 성능:
+46.63%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.81
$11.79
1주일 범위
$10.12
$11.79
52주 변동 폭
$5.33
$11.79
Niagen Bioscience Inc Stock (NAGE) Company Profile
명칭
Niagen Bioscience Inc
전화
310-388-6706
주소
10900 WILSHIRE BLVD, LOS ANGELES
NAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
11.73 | 834.96M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 개시 | Canaccord Genuity | Buy |
| 2022-08-16 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-08-11 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | 개시 | ROTH Capital | Buy |
| 2019-10-16 | 개시 | Oppenheimer | Outperform |
| 2019-02-14 | 개시 | B. Riley FBR | Buy |
| 2017-11-27 | 재개 | H.C. Wainwright | Buy |
| 2017-09-25 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-03 | 개시 | Rodman & Renshaw | Buy |
모두보기
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Price Target | NAGE Stock News - GuruFocus
Canaccord Analyst Recommends Buying Niagen Bioscience (NAGE) Stock | NAGE Stock News - GuruFocus
Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE) - Seeking Alpha
3 Stocks That May Be Trading Below Their Estimated Value - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighHere's Why - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Niagen Bioscience Reaches Analyst Target Price - Nasdaq
Ratios Uncovered: Breaking Down Niagen Bioscience Inc (NAGE)’s Trailing Twelve Months Metrics - DWinneX
Niagen Bioscience: Q1 Earnings Snapshot - New Haven Register
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - BioSpace
Niagen Bioscience Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com Nigeria
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings: EPS of $0.07 Beats Estimate, Revenue Surges to $30.5 Million - GuruFocus
Niagen Bioscience (NAGE) Reports Record Q1 Revenue with Strong G - GuruFocus
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Niagen Bioscience Q1 2025 slides: revenue jumps 38%, raises full-year outlook - Investing.com
Niagen Bioscience, Inc. SEC 10-Q Report - TradingView
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 | NAGE Stock News - GuruFocus
What's Next: Niagen Bioscience's Earnings Preview - Nasdaq
Niagen Bioscience Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Expands Clinical Network with New Clinics - GuruFocus
Niagen IV therapy expands to nearly 600 clinics nationwide By Investing.com - Investing.com India
Niagen IV therapy expands to nearly 600 clinics nationwide - Investing.com
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide | NAGE Stock News - GuruFocus
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Nasdaq
Niagen Bioscience adds aging expert to advisory board By Investing.com - Investing.com India
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board | NAGE Stock News - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advis - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board - The Joplin Globe
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Niagen Bioscience Inc (NAGE) 재무 분석
Niagen Bioscience Inc (NAGE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
6.48%
자본화:
|
볼륨(24시간):